Associated Papers
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2020
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Fujiwara Y et al.
Cancer Chemotherapy and Pharmacology, 2016
Select a paper to view details